Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Researchers present clinical outcomes of lenalidomide in patients with large B-cell lymphoma

Celgene International Sàrl today announced researchers at the annual meeting of the American Society of Clinical Oncology presented data from an evaluation of lenalidomide (REVLIMID) in patients with diffuse large B-cell lymphoma either with a germinal center B-cell or non-germinal center B-cell phenotype.

5 Jun 2010

Bayer to present Phase I and II clinical trial data of Alpharadin in CRPC at 46th ASCO

Bayer HealthCare will present a combined analysis from Phase I and II clinical trials evaluating the safety and efficacy of one of its lead investigational cancer treatments, Alpharadin™ (radium-223 chloride), in castration-resistant prostate cancer (CRPC) that has spread to the bones (metastases).

4 Jun 2010

Infinity announces Phase 2 clinical trial results of IPI-504 for NSCLC

Infinity Pharmaceuticals, Inc. today reported the results from its Phase 2 clinical trial of IPI-504, the company's i.v.-administered Hsp90 chaperone inhibitor, in patients with advanced non-small cell lung cancer (NSCLC). Data reported show that IPI-504 demonstrated clinical activity in patients with NSCLC, in particular among patients with oncogenic anaplastic lymphoma kinase (ALK) gene rearrangements.

4 Jun 2010

Ascalon International signs license agreement with CerRx

Ascalon International Inc., a newly established oncology drug developer, today announced an agreement for an exclusive option to license CerRx Inc's intravenous fenretinide product.

4 Jun 2010

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Merck announced today results from a new non-inferiority trial of an antiemetic regimen containing fosaprepitant dimeglumine administered as a single intravenous (IV) 150-mg dose in combination with a 5-HT3 antagonist and dexamethasone compared with a three-day regimen of aprepitant with a 5-HT3 antagonist and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving a first cycle of cisplatin-based chemotherapy.

4 Jun 2010

ASCO 2010 marks first anniversary of "Cancer Patient Statement of Principles"

The International Myeloma Foundation (IMF), the oldest and largest foundation dedicated to improving the life and care of myeloma patients, notes the 2010 Annual Meeting of the American Society for Clinical Oncology (ASCO) marks the first anniversary of the "Cancer Patient Statement of Principles."

4 Jun 2010

Roche's new dual-PCR target HIV-1 viral load test receives FDA approval

Roche Molecular Diagnostics announced today that the Food and Drug Administration (FDA) approved its new dual-PCR target HIV-1 viral load test to quantify the amount of virus in a patient's blood. The COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test, v2.0 is the first quantitative viral load test to amplify and detect two separate regions of a target genome and offers a fully automated and reliable solution for physicians to make informed treatment decisions for HIV-1 patients undergoing antiretroviral therapy.

4 Jun 2010

Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemotherapy

Abraxis BioScience, Inc. announced today that findings from a phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy.

4 Jun 2010

Life Technologies partners to create Genomic Cancer Care Alliance

Life Technologies Corporation today announced the creation of the Genomic Cancer Care Alliance to help people battling cancer gain access to treatment options found through analysis of their genomic information. Founding partners include Fox Chase Cancer Center, Scripps Genomic Medicine, and the Translational Genomics Research Institute (TGen). The announcement came during the Consumer Genetics Conference being held June 2-4 in Boston.

4 Jun 2010

ASTRO to honor David Larson and William McBride with prestigious Gold Medal award

David Larson, M.D., Ph.D., FASTRO, and William McBride, D.Sc., Ph.D., have been chosen to receive the American Society for Radiation Oncology's most prestigious award, the Gold Medal. They will be presented with this honor at the Awards Ceremony during ASTRO's 52nd Annual Meeting, taking place October 31 to November 4, 2010, in San Diego.

4 Jun 2010

Strategy for harnessing physics for health

Following a workshop hosted by the CERN European particle physics laboratory in February, doctors and physicists today published a strategy for harnessing physics for health. Techniques developed for physics research have a long history of application in medicine. Today's news recognises that synergy, and sets out a programme of strengthened collaboration.

4 Jun 2010

Stage III colon cancer patients treated with 5-FU-based chemotherapy after 1995 have improved overall survival

Patients with stage III colon cancer treated with 5-FU-based chemotherapy after complete surgical removal of their tumor after 1995 had improved overall survival with no change in time to recurrence compared to patients treated before 1995. In contrast, patients with stage II colon cancer treated after 1995 had longer time to recurrence and time from recurrence to death compared to those patients treated prior to 1995, according to Mayo Clinic and Gr Hospitalier Pitie-Salpetriere, Paris, researchers.

4 Jun 2010

Boehringer Ingelheim to present new data on BIBW 2992 for NSCLC and head-and-neck cancer at ASCO 2010

Boehringer Ingelheim will present promising new data on non-small cell lung cancer as well as head-and-neck cancer for its leading investigational compound BIBW 2992 at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, June 4-8, 2010.

4 Jun 2010

Functional profiling using EVA/PCD for prescribing treatment regimens for Stage IV NSCLC improve survival

A team of investigators at Rational Therapeutics, Inc. and the Malcolm Todd Cancer Institute (Long Beach, Calif.) has reported that functional profiling using ex-vivo analysis of programmed cell death (EVA/PCD) can be used to prescribe treatment regimens that double the response rate and survival in patients with Stage IV non-small cell lung cancer (NSCLC). The findings of their phase II clinical trial will be presented on Sunday, June 6th at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

4 Jun 2010

Study of methylphenidate for cancer-related fatigue benefits patients with stage III/IV disease

Cancer-related fatigue is often a major problem for cancer patients, beginning at diagnosis, during treatment and after completing therapy. Researchers at Mayo Clinic and the North Central Cancer Treatment Group (NCCTG) recently completed a study testing methylphenidate in the treatment of cancer-related fatigue and found that, while it did not improve fatigue for a broad group of patients, the data did not rule out a benefit for those with stage III/IV cancer.

4 Jun 2010

Merck launches Oncology Collaborative Trials Network

Today, Merck announced the launch of the Merck Oncology Collaborative Trials Network, a pioneering clinical trial network focusing on the development of Merck drug and vaccine candidates being investigated for the treatment and prevention of cancer. The global network comprises leading cancer research centers who will partner with Merck to speed the development of innovative treatments for a range of cancers.

4 Jun 2010

Physicians and researchers to present 16 abstracts on cancer research at ASCO 2010

The John Theurer Cancer Center at Hackensack University Medical Center announced today that its physicians and researchers will present 16 abstracts on treatment and diagnostic progress in many different areas of oncology during the Annual Meeting of American Society of Clinical Oncology in Chicago, IL from June 4-8.

4 Jun 2010

Chemotherapy-induced amenorrhea improves survival in premenopausal women with early stage breast cancer

Chemotherapy-induced amenorrhea in premenopausal women being treated for early stage breast cancer was associated with significantly improved patient survival, according to a study published this week in the New England Journal of Medicine by the National Surgical Adjuvant Breast and Bowel Project (NSABP) in collaboration with leading US cancer centers and cooperative cancer research groups.

4 Jun 2010

New therapy mounts double-barreled attack on leukemia, report UF researchers

A new therapy mounts a double-barreled attack on leukemia, targeting not just the cancer cells but also the environment in which those cells live and grow, University of Florida researchers report.

4 Jun 2010

Merrimack's Phase 1/2 trial design of MM-111 in HER2 positive cancer to be presented at 2010 ASCO

Merrimack Pharmaceuticals, Inc. announced today that the design of their Phase 1/2 trial investigating the safety and tolerability of MM-111 in HER2 positive cancer patients will be presented at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 4-8, 2010, in Chicago, Illinois.

4 Jun 2010

Oncology News and Research

Further Reading

Researchers present clinical outcomes of lenalidomide in patients with large B-cell lymphoma

Bayer to present Phase I and II clinical trial data of Alpharadin in CRPC at 46th ASCO

Infinity announces Phase 2 clinical trial results of IPI-504 for NSCLC

Ascalon International signs license agreement with CerRx

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

ASCO 2010 marks first anniversary of "Cancer Patient Statement of Principles"

Roche's new dual-PCR target HIV-1 viral load test receives FDA approval

Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemotherapy

Life Technologies partners to create Genomic Cancer Care Alliance

ASTRO to honor David Larson and William McBride with prestigious Gold Medal award

Strategy for harnessing physics for health

Stage III colon cancer patients treated with 5-FU-based chemotherapy after 1995 have improved overall survival

Boehringer Ingelheim to present new data on BIBW 2992 for NSCLC and head-and-neck cancer at ASCO 2010

Functional profiling using EVA/PCD for prescribing treatment regimens for Stage IV NSCLC improve survival

Study of methylphenidate for cancer-related fatigue benefits patients with stage III/IV disease

Merck launches Oncology Collaborative Trials Network

Physicians and researchers to present 16 abstracts on cancer research at ASCO 2010

Chemotherapy-induced amenorrhea improves survival in premenopausal women with early stage breast cancer

New therapy mounts double-barreled attack on leukemia, report UF researchers

Merrimack's Phase 1/2 trial design of MM-111 in HER2 positive cancer to be presented at 2010 ASCO

Cancer Research eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News